To define tumor inflammation, a key prognostic indicator and predictor to immune therapy responses (Kandalaft et al., 2022), we assessed the T and B tumor-infiltrating lymphocytes (TILs) in the five different tumor types described above, using dual CD3/CD20 (also known as MS4A1) immunohistochemistry (IHC). This evidence concerns the gene MS4A1 and neoplasm.